Progress of hematologic malignancy related gene mutations in patients with chronic myelogenous leukemia / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 701-704, 2021.
Article
en Zh
| WPRIM
| ID: wpr-907237
Biblioteca responsable:
WPRO
ABSTRACT
Chronic myelogenous leukemia (CML) is a myeloproliferative disease characterized by heterotopic Ph chromosome. Tyrosine kinase inhibitor (TKI) has significantly improved the prognosis of patients with CML. Cytogenetic and molecular monitoring for assessing the therapeutic efficacy of TKI to guide disease management has become an important component of CML therapy. However, the expanded genomic analysis of the disease diagnosis, transformation and drug resistance has not been fully explored in CML research. The paper reviews the frequency and type of gene mutations at initial diagnosis and the time of treatment failure and transformation, and investigates the relationship between genetic mutations and the prognosis of CML patients in the diagnosis and treatment.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Journal of Leukemia & Lymphoma
Año:
2021
Tipo del documento:
Article